Henry A Chen, MD
Cardiovascular Disease (Cardiology) · Pleasanton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 15
- 4 carriers
- Office
- 1
- Since medical school
- 28 years
- Yale University School of Medicine, 1998
Offices
1 location
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
15 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (925) 460-9899 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
15 of 15 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A81471 · Current
Licensed to practise in California · since 2002 · expires 2028-04-30 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$111,120
Medicare paid this office $111,120 for 776 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 146 | $38,913 | $107 |
| New patient visit (45+ min) | 51 | $7,117 | $140 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $6,424 | $401 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 579 | $5,467 | $6 |
| Programming of dual lead pacemaker system | 51 | $3,216 | $30 |
See all 13 services
| Return visit (30+ min) | 146 | $38,913 | $107 |
| New patient visit (45+ min) | 51 | $7,117 | $140 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $6,424 | $401 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 579 | $5,467 | $6 |
| Programming of dual lead pacemaker system | 51 | $3,216 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,507 | $139 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 39 | $2,158 | $55 |
| Short return visit (20+ min) | 15 | $2,056 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,272 | $64 |
| Programming of dual lead pacemaker system | 15 | $447 | $30 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 12 | $222 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 17 | $202 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $199 | $9 |
Procedures Medicare counted
| Pacemaker insertion or repair | 12 | More than 63% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Insertion of pacemaker and upper and lower heart chamber electrode | 22 | – | 13 | 16 | 24 | 16 |
| Insertion of implantable defibrillator system | 11 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
776 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 23% · Women 53% · Also on Medicaid 23% · Health risk score 1.81. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Chronic kidney disease 48% · Coronary heart disease 45% · Atrial fibrillation 41% · Heart failure 36% · Diabetes 34% · Cancer 24% · COPD 21% · Depression 21% · Dementia 17% · Stroke 15%.
The office billed $253,367, Medicare allowed $144,375 and paid $111,120; for 1,694 services of 45 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 776 | 1,694 | 77 | 1.81 | $253,367 | $111,120 |
| 2023 | 641 | 1,681 | 77 | 1.96 | $275,930 | $133,594 |
| 2022 | 547 | 1,317 | 76 | 1.83 | $224,759 | $106,123 |
| 2021 | 581 | 1,233 | 77 | 2.01 | $174,605 | $89,656 |
| 2020 | 580 | 1,015 | 77 | 2.08 | $100,338 | $46,064 |
| 2019 | 614 | 1,507 | 77 | 1.96 | $246,300 | $112,244 |
| 2018 | 382 | 1,005 | 76 | 2.00 | $164,410 | $73,444 |
| 2017 | 110 | 536 | 78 | 1.67 | $126,879 | $58,787 |
| 2016 | 86 | 381 | 76 | 1.57 | $79,015 | $37,540 |
| 2015 | 711 | 2,408 | 77 | 1.94 | $578,943 | $169,088 |
| 2014 | 1,039 | 3,359 | 76 | 1.79 | $854,963 | $230,331 |
| 2013 | 1,553 | 4,647 | 74 | 2.01 | $867,979 | $241,559 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 133 | $40,970 | $118 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 24 | $10,719 | $447 |
| New patient visit (45+ min) | 55 | $8,314 | $151 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 450 | $5,069 | $7 |
| Short return visit (20+ min) | 20 | $3,924 | $85 |
| Critical care, first 30-74 minutes | 12 | $3,703 | $185 |
| Programming of dual lead pacemaker system | 51 | $3,633 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,297 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $2,767 | $154 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $2,381 | $61 |
| Programming of multiple lead implantable defibrillator system | 13 | $1,913 | $55 |
| Programming of dual lead pacemaker system | 14 | $467 | $33 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 33 | $370 | $11 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 15 | $312 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 20 | $248 | $12 |
2022: 12 services
| Return visit (30+ min) | 115 | $33,664 | $116 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 16 | $7,249 | $453 |
| New patient visit (45+ min) | 43 | $6,488 | $151 |
| Short return visit (20+ min) | 27 | $4,761 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 377 | $3,857 | $7 |
| Programming of dual lead pacemaker system | 42 | $2,905 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,146 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,096 | $175 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 26 | $1,689 | $63 |
| Programming of dual lead pacemaker system | 11 | $374 | $34 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 26 | $291 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 15 | $195 | $13 |
2021: 12 services
| Return visit (30+ min) | 88 | $28,275 | $119 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 13 | $6,001 | $462 |
| New patient visit (45+ min) | 36 | $5,610 | $156 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 435 | $4,580 | $7 |
| Short return visit (20+ min) | 22 | $3,617 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $3,147 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,685 | $179 |
| Programming of dual lead pacemaker system | 33 | $1,948 | $35 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 23 | $1,596 | $64 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 24 | $278 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 12 | $237 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 15 | $212 | $13 |
2020: 7 services
| Return visit (30+ min) | 88 | $15,972 | $94 |
| New patient visit (45+ min) | 33 | $4,771 | $145 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 448 | $4,642 | $8 |
| Short return visit (20+ min) | 18 | $1,671 | $64 |
| Programming of dual lead pacemaker system | 29 | $1,306 | $35 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 11 | $739 | $67 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 12 | $143 | $11 |
2019: 15 services
| Return visit (30+ min) | 96 | $21,669 | $101 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 22 | $10,047 | $457 |
| New patient visit (45+ min) | 64 | $9,652 | $151 |
| Insertion of implantable defibrillator system | 11 | $8,849 | $804 |
| Short return visit (20+ min) | 42 | $6,142 | $69 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 437 | $4,676 | $8 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,475 | $179 |
| Programming of dual lead pacemaker system | 51 | $4,315 | $34 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $2,382 | $64 |
| Programming of multiple lead implantable defibrillator system | 14 | $1,992 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $1,188 | $66 |
| Programming of dual lead pacemaker system | 12 | $415 | $35 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 30 | $336 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 16 | $318 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $214 | $13 |
2018: 12 services
| Return visit (30+ min) | 66 | $13,603 | $92 |
| Insertion of implantable defibrillator system | 13 | $9,737 | $749 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $6,371 | $425 |
| New patient visit (45+ min) | 39 | $5,547 | $142 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,405 | $169 |
| Short return visit (20+ min) | 25 | $3,477 | $64 |
| Programming of dual lead pacemaker system | 37 | $3,123 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $2,678 | $61 |
| Programming of multiple lead implantable defibrillator system | 20 | $2,429 | $50 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 256 | $2,407 | $7 |
| Programming of dual lead pacemaker system | 13 | $455 | $33 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $206 | $10 |
2017: 11 services
| Return visit (30+ min) | 51 | $12,416 | $91 |
| Insertion of implantable defibrillator system | 13 | $9,764 | $751 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 15 | $6,409 | $427 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,294 | $172 |
| New patient visit (45+ min) | 32 | $4,271 | $133 |
| Programming of dual lead pacemaker system | 37 | $2,841 | $32 |
| Short return visit (20+ min) | 25 | $1,984 | $60 |
| Programming of multiple lead implantable defibrillator system | 14 | $1,664 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,227 | $61 |
| Programming of dual lead pacemaker system | 12 | $396 | $33 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 23 | $238 | $10 |
2016: 7 services
| Return visit (30+ min) | 45 | $9,442 | $93 |
| New patient visit (45+ min) | 23 | $3,274 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,902 | $60 |
| Programming of dual lead pacemaker system | 30 | $2,277 | $33 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,874 | $170 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,258 | $114 |
| Short return visit (20+ min) | 16 | $1,156 | $61 |
2015: 17 services
| Return visit (30+ min) | 325 | $60,549 | $84 |
| Programming of dual lead pacemaker system | 194 | $13,654 | $39 |
| Short return visit (20+ min) | 117 | $8,756 | $60 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 18 | $8,057 | $448 |
| New patient visit (45+ min) | 47 | $6,377 | $136 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 249 | $5,878 | $14 |
| Programming of multiple lead implantable defibrillator system | 42 | $5,732 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $5,697 | $62 |
| Programming of dual lead implantable defibrillator system | 41 | $4,948 | $52 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 15 | $3,157 | $210 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $2,488 | $89 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 24 | $1,328 | $55 |
| Programming of single lead pacemaker system | 28 | $1,321 | $31 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 17 | $1,220 | $72 |
| Programming of single lead implantable defibrillator system | 14 | $1,188 | $44 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 20 | $1,175 | $59 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 49 | $411 | $7 |
2014: 25 services
| Return visit (30+ min) | 295 | $62,681 | $87 |
| Programming of dual lead pacemaker system | 219 | $21,226 | $38 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 34 | $15,106 | $444 |
| Insertion of implantable defibrillator system | 20 | $14,480 | $724 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 16 | $10,767 | $673 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 102 | $10,527 | $61 |
| Short return visit (20+ min) | 109 | $8,497 | $58 |
| Programming of multiple lead implantable defibrillator system | 48 | $8,224 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 37 | $8,221 | $211 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 349 | $7,501 | $14 |
| Programming of dual lead implantable defibrillator system | 46 | $7,238 | $57 |
| New patient visit (45+ min) | 47 | $6,697 | $142 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 12 | $4,644 | $387 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $4,443 | $89 |
| Insertion of tube in upper and/or lower heart chambers to record and identify origin of abnormal heart rhythm | 19 | $4,231 | $223 |
| Removal and replacement of dual lead permanent pacemaker | 11 | $3,347 | $304 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 39 | $3,109 | $78 |
| Programming of single lead pacemaker system | 35 | $1,987 | $29 |
| Programming of single lead implantable defibrillator system | 16 | $1,980 | $44 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 34 | $1,734 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 204 | $1,702 | $7 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 17 | $1,593 | $94 |
| Programming of heart rhythm stimulation after drug infusion | 11 | $1,466 | $133 |
| Short return visit | 13 | $395 | $30 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 18 | $111 | $6 |
2013: 22 services
| Return visit (30+ min) | 281 | $70,043 | $88 |
| Programming of dual lead pacemaker system | 197 | $18,218 | $36 |
| Insertion of implantable defibrillator system | 23 | $16,487 | $717 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 35 | $14,620 | $418 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 139 | $13,939 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 378 | $10,133 | $16 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 791 | $9,401 | $7 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 12 | $7,988 | $666 |
| Programming of dual lead implantable defibrillator system | 49 | $7,773 | $57 |
| Short return visit (20+ min) | 99 | $7,759 | $59 |
| Programming of multiple lead implantable defibrillator system | 44 | $7,053 | $58 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 34 | $6,023 | $177 |
| New patient visit (45+ min) | 40 | $5,628 | $141 |
| Insertion of tube in upper and/or lower heart chambers to record and identify origin of abnormal heart rhythm | 12 | $4,645 | $221 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $3,415 | $53 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 39 | $3,329 | $77 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $2,885 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $2,331 | $86 |
| Programming of single lead pacemaker system | 29 | $1,743 | $31 |
| Programming of single lead implantable defibrillator system | 17 | $1,587 | $39 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 11 | $899 | $60 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $437 | $34 |
Medicaid work
$1,537 in 2024
Medicaid paid $1,537 for 335 billed services this clinician did in 2024, up to 68 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 335 | $1,537 |
| 2024 | 335 | 1 | 68 | $1,537 |
| 2023 | 404 | 1 | 72 | $2,013 |
| 2022 | 269 | 1 | 52 | $1,262 |
| 2021 | 196 | 1 | 37 | $738 |
| 2020 | 110 | 1 | 26 | $472 |
| 2019 | 175 | 1 | 39 | $706 |
| 2018 | 47 | 1 | 22 | $165 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 404 | $2,013 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 269 | $1,262 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 196 | $738 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 110 | $472 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 175 | $706 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 47 | $165 |
Drugs they prescribed that Part D paid
$299,506
Pharmacies billed $299,506 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,045) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
796 generic and 249 brand-name prescriptions · $299,506 in drug cost · 55 antibiotic prescriptions to 42 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 122 | $163,759 | $1,342 |
| Multaq | 26 | $50,780 | $1,953 |
| Xarelto | 45 | $48,627 | $1,081 |
| Diltiazem 24hr Er (Cd) | 18 | $1,639 | $91 |
| Metoprolol | 96 | $1,557 | $16 |
See all 22 drugs
| Eliquis | 122 | $163,759 | $1,342 |
| Multaq | 26 | $50,780 | $1,953 |
| Xarelto | 45 | $48,627 | $1,081 |
| Diltiazem 24hr Er (Cd) | 18 | $1,639 | $91 |
| Metoprolol | 96 | $1,557 | $16 |
| Propafenone Hcl Er | 11 | $934 | $85 |
| Amlodipine Besylate | 128 | $881 | $7 |
| Diltiazem 24hr Er | 32 | $793 | $25 |
| Carvedilol | 56 | $599 | $11 |
| Atorvastatin | 47 | $587 | $12 |
| Isosorbide Mononitrate Er | 12 | $536 | $45 |
| Amiodarone | 21 | $507 | $24 |
| Losartan | 56 | $484 | $9 |
| Metoprolol | 49 | $437 | $9 |
| Potassium Chloride | 15 | $401 | $27 |
| Lisinopril | 30 | $331 | $11 |
| Hydralazine | 20 | $310 | $15 |
| Digoxin | 11 | $286 | $26 |
| Doxycycline Hyclate | 29 | $219 | $8 |
| Hydrochlorothiazide | 20 | $135 | $7 |
| Furosemide | 20 | $96 | $5 |
| Amoxicillin | 12 | $28 | $2 |
Year by year
| 2024 | 1,045 | 215 | 0% (0) | 24% | $299,506 |
| 2023 | 945 | 180 | None | 23% | $289,317 |
| 2022 | 743 | 143 | 0% (0) | None | $193,947 |
| 2021 | 696 | 123 | 0% (0) | 20% | $166,327 |
| 2020 | 617 | 101 | 0% (0) | 25% | $146,698 |
| 2019 | 425 | 87 | None | 34% | $106,885 |
| 2018 | 264 | 57 | None | None | $67,374 |
| 2017 | 258 | 66 | 0% (0) | None | $39,512 |
| 2016 | 726 | 180 | 0% (0) | None | $62,662 |
| 2015 | 2,635 | 316 | 0% (0) | 21% | $213,894 |
| 2014 | 2,279 | 263 | None | 21% | $196,283 |
| 2013 | 2,336 | 269 | 1% (11) | 21% | $174,552 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Eliquis | 124 | $168,123 | $1,356 |
| Xarelto | 33 | $54,829 | $1,661 |
| Multaq | 24 | $33,276 | $1,386 |
| Diltiazem 24hr Er (Cd) | 18 | $2,735 | $152 |
| Metoprolol | 107 | $2,263 | $21 |
| Amlodipine Besylate | 94 | $1,136 | $12 |
| Diltiazem 24hr Er | 26 | $1,095 | $42 |
| Amiodarone | 24 | $1,016 | $42 |
| Atorvastatin | 46 | $728 | $16 |
| Isosorbide Mononitrate Er | 14 | $606 | $43 |
| Carvedilol | 42 | $515 | $12 |
| Lisinopril | 14 | $486 | $35 |
| Potassium Chloride | 14 | $465 | $33 |
| Losartan | 43 | $428 | $10 |
| Metoprolol | 40 | $395 | $10 |
| Digoxin | 17 | $356 | $21 |
| Doxycycline Hyclate | 29 | $336 | $12 |
| Losartan-Hydrochlorothiazide | 15 | $193 | $13 |
| Furosemide | 22 | $156 | $7 |
| Hydrochlorothiazide | 22 | $111 | $5 |
2022: 19 drugs
| Eliquis | 95 | $103,052 | $1,085 |
| Xarelto | 29 | $36,275 | $1,251 |
| Multaq | 14 | $29,208 | $2,086 |
| Diltiazem 24hr Er (Cd) | 29 | $3,102 | $107 |
| Metoprolol | 92 | $2,065 | $22 |
| Amiodarone | 20 | $829 | $41 |
| Amlodipine Besylate | 66 | $583 | $9 |
| Atorvastatin | 43 | $570 | $13 |
| Potassium Chloride | 18 | $480 | $27 |
| Diltiazem 24hr Er | 12 | $458 | $38 |
| Digoxin | 17 | $434 | $26 |
| Dilt-Xr | 11 | $418 | $38 |
| Carvedilol | 34 | $407 | $12 |
| Losartan | 25 | $382 | $15 |
| Doxycycline Hyclate | 22 | $298 | $14 |
| Metoprolol | 20 | $119 | $6 |
| Lisinopril | 16 | $89 | $6 |
| Hydrochlorothiazide | 16 | $55 | $3 |
| Furosemide | 12 | $48 | $4 |
2021: 20 drugs
| Eliquis | 75 | $82,641 | $1,102 |
| Xarelto | 24 | $35,281 | $1,470 |
| Multaq | 12 | $19,255 | $1,605 |
| Metoprolol | 75 | $1,952 | $26 |
| Diltiazem 24hr Er (Cd) | 37 | $1,883 | $51 |
| Digoxin | 19 | $732 | $39 |
| Diltiazem 24hr Er | 14 | $684 | $49 |
| Potassium Chloride | 16 | $514 | $32 |
| Amiodarone | 20 | $495 | $25 |
| Atorvastatin | 33 | $470 | $14 |
| Losartan | 22 | $383 | $17 |
| Doxycycline Hyclate | 20 | $288 | $14 |
| Losartan-Hydrochlorothiazide | 11 | $262 | $24 |
| Metoprolol | 21 | $246 | $12 |
| Carvedilol | 26 | $226 | $9 |
| Amlodipine Besylate | 56 | $207 | $4 |
| Triamterene-Hydrochlorothiazid | 11 | $148 | $13 |
| Lisinopril | 18 | $118 | $7 |
| Furosemide | 14 | $106 | $8 |
| Hydrochlorothiazide | 14 | $50 | $4 |
2020: 20 drugs
| Eliquis | 71 | $67,544 | $951 |
| Multaq | 34 | $35,060 | $1,031 |
| Xarelto | 19 | $23,317 | $1,227 |
| Metoprolol | 45 | $2,297 | $51 |
| Cartia Xt | 17 | $1,148 | $68 |
| Diltiazem 24hr Er (Cd) | 15 | $842 | $56 |
| Diltiazem 24hr Er | 11 | $735 | $67 |
| Digoxin | 13 | $592 | $46 |
| Verapamil Er | 11 | $491 | $45 |
| Amiodarone | 15 | $470 | $31 |
| Metoprolol | 28 | $460 | $16 |
| Carvedilol | 31 | $398 | $13 |
| Losartan-Hydrochlorothiazide | 12 | $397 | $33 |
| Potassium Chloride | 13 | $380 | $29 |
| Amlodipine Besylate | 48 | $372 | $8 |
| Atorvastatin | 23 | $361 | $16 |
| Losartan | 15 | $278 | $19 |
| Doxycycline Hyclate | 22 | $260 | $12 |
| Lisinopril | 20 | $111 | $6 |
| Hydrochlorothiazide | 20 | $92 | $5 |
2019: 13 drugs
| Eliquis | 60 | $42,941 | $716 |
| Multaq | 31 | $26,386 | $851 |
| Xarelto | 28 | $20,028 | $715 |
| Metoprolol | 24 | $1,020 | $42 |
| Digoxin | 13 | $739 | $57 |
| Cartia Xt | 12 | $515 | $43 |
| Amlodipine Besylate | 27 | $294 | $11 |
| Amiodarone | 12 | $294 | $24 |
| Metoprolol | 23 | $225 | $10 |
| Atorvastatin | 11 | $222 | $20 |
| Carvedilol | 24 | $183 | $8 |
| Lisinopril | 12 | $88 | $7 |
| Hydrochlorothiazide | 11 | $85 | $8 |
2018: 8 drugs
| Eliquis | 31 | $24,371 | $786 |
| Multaq | 17 | $19,448 | $1,144 |
| Xarelto | 14 | $12,277 | $877 |
| Digoxin | 12 | $1,015 | $85 |
| Metoprolol | 18 | $744 | $41 |
| Carvedilol | 17 | $171 | $10 |
| Amlodipine Besylate | 13 | $129 | $10 |
| Metoprolol | 18 | $103 | $6 |
2017: 9 drugs
| Multaq | 12 | $8,508 | $709 |
| Eliquis | 14 | $6,994 | $500 |
| Diltiazem 24hr Er | 26 | $1,318 | $51 |
| Digoxin | 14 | $1,138 | $81 |
| Metoprolol | 13 | $457 | $35 |
| Atorvastatin | 20 | $342 | $17 |
| Doxycycline Hyclate | 13 | $196 | $15 |
| Amlodipine Besylate | 13 | $126 | $10 |
| Metoprolol | 16 | $95 | $6 |
2016: 23 drugs
| Xarelto | 26 | $12,569 | $483 |
| Eliquis | 27 | $11,559 | $428 |
| Metoprolol | 68 | $2,356 | $35 |
| Diltiazem 24hr Er | 29 | $1,926 | $66 |
| Digoxin | 40 | $1,654 | $41 |
| Atorvastatin | 70 | $1,509 | $22 |
| Diltiazem 24hr Cd | 17 | $936 | $55 |
| Valsartan | 13 | $903 | $69 |
| Amiodarone | 22 | $643 | $29 |
| Cartia Xt | 22 | $631 | $29 |
| Warfarin | 28 | $586 | $21 |
| Doxycycline Hyclate | 16 | $312 | $19 |
| Amlodipine Besylate | 30 | $288 | $10 |
| Carvedilol | 39 | $265 | $7 |
| Pravastatin | 13 | $258 | $20 |
| Atenolol | 24 | $189 | $8 |
| Lisinopril | 21 | $160 | $8 |
| Clopidogrel | 11 | $160 | $15 |
| Metoprolol | 27 | $146 | $5 |
| Simvastatin | 12 | $125 | $10 |
| Furosemide | 11 | $87 | $8 |
| Losartan | 11 | $57 | $5 |
| Hydrochlorothiazide | 13 | $36 | $3 |
2015: 40 drugs
| Xarelto | 138 | $68,352 | $495 |
| Eliquis | 86 | $29,924 | $348 |
| Pradaxa | 43 | $18,784 | $437 |
| Multaq | 29 | $14,411 | $497 |
| Crestor | 27 | $10,867 | $402 |
| Metoprolol | 223 | $8,688 | $39 |
| Digoxin | 117 | $5,471 | $47 |
| Diltiazem 24hr Er | 45 | $3,894 | $87 |
| Digox | 62 | $3,017 | $49 |
| Cartia Xt | 86 | $2,738 | $32 |
| Warfarin | 118 | $2,417 | $20 |
| Atorvastatin | 120 | $2,081 | $17 |
| Pravastatin | 63 | $2,008 | $32 |
| Valsartan | 24 | $1,960 | $82 |
| Diltiazem Er | 41 | $1,838 | $45 |
| Fenofibrate | 12 | $1,719 | $143 |
| Amiodarone | 100 | $1,553 | $16 |
| Carvedilol | 207 | $1,417 | $7 |
| Diltiazem 24hr Cd | 37 | $1,201 | $32 |
| Lisinopril | 163 | $883 | $5 |
| Nitrostat | 19 | $725 | $38 |
| Dilt-Xr | 16 | $707 | $44 |
| Metoprolol | 108 | $707 | $7 |
| Potassium Chloride | 28 | $671 | $24 |
| Atenolol | 113 | $655 | $6 |
| Omega-3 Acid Ethyl Esters | 12 | $627 | $52 |
| Isosorbide Mononitrate Er | 25 | $532 | $21 |
| Amlodipine Besylate | 63 | $465 | $7 |
| Doxycycline Hyclate | 11 | $353 | $32 |
| Simvastatin | 48 | $353 | $7 |
| Losartan | 26 | $345 | $13 |
| Omeprazole | 16 | $331 | $21 |
| Furosemide | 49 | $318 | $6 |
| Pantoprazole | 20 | $310 | $15 |
| Clopidogrel | 22 | $308 | $14 |
| Spironolactone | 32 | $217 | $7 |
| Depo-Testosterone | 11 | $206 | $19 |
| Benazepril | 15 | $181 | $12 |
| Escitalopram | 14 | $175 | $12 |
| Hydrochlorothiazide | 51 | $165 | $3 |
2014: 42 drugs
| Xarelto | 124 | $51,540 | $416 |
| Multaq | 41 | $19,429 | $474 |
| Pradaxa | 46 | $15,986 | $348 |
| Eliquis | 37 | $13,779 | $372 |
| Metoprolol | 194 | $11,013 | $57 |
| Crestor | 26 | $7,509 | $289 |
| Diltiazem 24hr Er | 56 | $5,103 | $91 |
| Diovan | 12 | $4,676 | $390 |
| Diltiazem 24hr Cd | 32 | $4,538 | $142 |
| Digoxin | 94 | $4,304 | $46 |
| Diltiazem Er | 95 | $3,247 | $34 |
| Amiodarone | 60 | $3,168 | $53 |
| Clonidine | 14 | $3,044 | $217 |
| Digox | 67 | $2,774 | $41 |
| Pacerone | 11 | $2,230 | $203 |
| Carvedilol | 173 | $1,665 | $10 |
| Warfarin | 98 | $1,490 | $15 |
| Diltiazem 12hr Er | 15 | $1,446 | $96 |
| Lovaza | 14 | $1,397 | $100 |
| Pravastatin | 41 | $1,282 | $31 |
| Atorvastatin | 41 | $1,046 | $26 |
| Lisinopril | 135 | $817 | $6 |
| Metoprolol | 107 | $771 | $7 |
| Amlodipine Besylate | 72 | $646 | $9 |
| Propranolol Hcl Er | 14 | $593 | $42 |
| Doxycycline Hyclate | 15 | $589 | $39 |
| Isosorbide Mononitrate Er | 30 | $558 | $19 |
| Atenolol | 69 | $540 | $8 |
| Hydralazine | 27 | $504 | $19 |
| Fenofibrate | 16 | $486 | $30 |
| Simvastatin | 68 | $466 | $7 |
| Depo-Testosterone | 13 | $454 | $35 |
| Verapamil Er | 12 | $350 | $29 |
| Omeprazole | 42 | $349 | $8 |
| Potassium Chloride | 16 | $322 | $20 |
| Levothyroxine | 14 | $244 | $17 |
| Hydrochlorothiazide | 72 | $243 | $3 |
| Benazepril | 18 | $228 | $13 |
| Losartan | 21 | $224 | $11 |
| Pantoprazole | 18 | $218 | $12 |
| Furosemide | 26 | $185 | $7 |
| Nitrostat | 12 | $184 | $15 |
2013: 39 drugs
| Xarelto | 142 | $50,527 | $356 |
| Pradaxa | 49 | $16,654 | $340 |
| Multaq | 33 | $15,239 | $462 |
| Metoprolol | 172 | $10,290 | $60 |
| Diovan | 32 | $7,294 | $228 |
| Crestor | 26 | $6,948 | $267 |
| Diltiazem 24hr Cd | 44 | $5,902 | $134 |
| Diltiazem 24hr Er | 69 | $5,221 | $76 |
| Diltiazem Er | 93 | $4,132 | $44 |
| Clonidine | 11 | $3,613 | $328 |
| Carvedilol | 168 | $2,234 | $13 |
| Lovaza | 24 | $1,866 | $78 |
| Atorvastatin | 37 | $1,485 | $40 |
| Warfarin | 105 | $1,474 | $14 |
| Amlodipine Besylate | 126 | $1,228 | $10 |
| Dilt-Xr | 28 | $1,119 | $40 |
| Amiodarone | 65 | $1,071 | $16 |
| Isosorbide Mononitrate Er | 37 | $956 | $26 |
| Lisinopril | 136 | $917 | $7 |
| Hydralazine | 37 | $802 | $22 |
| Metoprolol | 98 | $797 | $8 |
| Doxycycline Hyclate | 23 | $780 | $34 |
| Digox | 82 | $768 | $9 |
| Potassium Chloride | 28 | $629 | $22 |
| Fenofibrate | 15 | $589 | $39 |
| Simvastatin | 61 | $550 | $9 |
| Digoxin | 60 | $485 | $8 |
| Atenolol | 66 | $480 | $7 |
| Pravastatin | 23 | $466 | $20 |
| Propranolol | 15 | $437 | $29 |
| Omeprazole | 30 | $425 | $14 |
| Benazepril | 22 | $395 | $18 |
| Hydrochlorothiazide | 95 | $365 | $4 |
| Furosemide | 52 | $337 | $6 |
| Klor-Con 10 | 11 | $299 | $27 |
| Lanoxin | 17 | $227 | $13 |
| Levothyroxine | 15 | $125 | $8 |
| Pantoprazole | 12 | $110 | $9 |
| Famotidine | 11 | $61 | $6 |
Money from drug and device companies
$748 in 2025
| 2025 | 6 | 27 | None | $748 |
| 2024 | 2 | 4 | None | $132 |
| 2023 | 5 | 16 | None | $517 |
| 2022 | 5 | 8 | None | $216 |
| 2021 | 1 | 2 | None | $29 |
| 2020 | 1 | 1 | None | $12 |
| 2019 | 6 | 28 | None | $2,077 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Therapies | $236 | 8 payments
|
| Amgen | Repatha | $233 | 9 payments
|
| Abbott Laboratories | Aveir | $117 | 5 payments
|
| Cordis US | Mynx Control Venous | $102 | 3 payments
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $46 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
See all 27 published payments
| Abbott Laboratories | Meals · 2025-12-16 | Perclose Prostyle | $30 |
| Amgen | Meals · 2025-12-03 | Repatha | $31 |
| Boston Scientific | Meals · 2025-11-12 | Endotak Reliance S | $30 |
| Boston Scientific | Meals · 2025-10-29 | Lux-Dx Insertable Cardiac Monitor | $17 |
| Amgen | Meals · 2025-10-29 | Repatha | $28 |
| Boston Scientific | Meals · 2025-10-02 | Emblem Mri S-Icd | $44 |
| Abbott Laboratories | Meals · 2025-09-26 | Aveir | $23 |
| Abbott Laboratories | Meals · 2025-09-26 | Aveir | $24 |
| Amgen | Meals · 2025-09-24 | Repatha | $34 |
| Boston Scientific | Meals · 2025-09-17 | Lux-Dx Insertable Cardiac Monitor | $6 |
| Amgen | Meals · 2025-09-10 | Repatha | $35 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $22 |
| Abbott Laboratories | Meals · 2025-08-18 | Aveir | $18 |
| Cordis US | Meals · 2025-08-15 | Mynx Control Venous | $45 |
| Amgen | Meals · 2025-07-23 | Repatha | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-18 | Farxiga | $14 |
| Boston Scientific | Meals · 2025-07-09 | Lux-Dx Insertable Cardiac Monitor | $25 |
| Amgen | Meals · 2025-07-09 | Repatha | $10 |
| Cordis US | Meals · 2025-06-19 | Mynx Control Venous | $23 |
| Boston Scientific | Meals · 2025-05-29 | Farapulse | $31 |
| Boston Scientific | Meals · 2025-05-21 | Lux-Dx Insertable Cardiac Monitor | $8 |
| Amgen | Meals · 2025-05-21 | Repatha | $27 |
| Cordis US | Meals · 2025-05-16 | Mynx Control Venous | $34 |
| Cardiva Medical | Meals · 2025-05-08 | Cardiva Vascade Mvp Vvcs 6-12f | $46 |
| Boston Scientific | Meals · 2025-04-24 | General - Therapies | $75 |
| Amgen | Meals · 2025-02-12 | Repatha | $5 |
| Amgen | Meals · 2025-02-05 | Repatha | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $132
| Boston Scientific | Lux-Dx Insertable Cardiac Monitor | $78 | 2 payments
|
| iRhythm Technologies | Zio Xt Patch | $53 | 2 payments
|
2023: $517
| Medtronic | Micra | $338 | 9 payments
|
| Philips Electronics North America | (5044) Mcot | $67 | 2 payments
|
| Boston Scientific | Latitude Communicator Power Supply | $39 | 2 payments
|
| Abbott Laboratories | Perclose Prostyle | $39 | 2 payments
|
| Biotronik | Acticor 7 Vr-T Dx | $34 | 1 payment
|
2022: $216
| Boston Scientific | General - Therapies | $84 | 2 payments
|
| Medtronic | Reveal Linq | $51 | 3 payments
|
| Philips Electronics North America | (5044) Mcot | $43 | 1 payment
|
| Abbott Laboratories | Confirm Rx | $24 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $14 | 1 payment
|
2021: $29
| AstraZeneca Pharmaceuticals LP | None | $29 | 2 payments
|
2020: $12
| AstraZeneca Pharmaceuticals LP | Brilinta | $12 | 1 payment
|
2019: $2,077
| Medtronic Vascular | Arctic Front | $1,727 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $136 | 10 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $117 | 2 payments
|
| Allergan | Zenpep | $50 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $32 | 2 payments
|
| Abbott Laboratories | Confirm Rx | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1154526895
- Licence
- CA A81471California A81471: Current · expires 2028-04-30
- Trained
- Yale University School of Medicine, 1998 · 28 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X)
- Mailing address
- 2101 Vale Rd, #201, San Pablo, CA, 94806
- NPI first listed
- 2007-06-20
- NPI last updated
- 2008-01-31
This is when the NPI record was last certified, not a medical board exam.